BRIEF published on 07/06/2026 at 22:10, 30 days 17 hours ago Abivax Completes its $920 Million Public Offering Biotechnology Actions Funding Abivax Public Offering
BRIEF published on 07/06/2026 at 22:10, 30 days 17 hours ago Abivax lève 920 millions de dollars lors d'une offre publique Biotechnologie Abivax Rectocolite Hémorragique Offre Publique Actions De Dépôt Américaines
BRIEF published on 07/06/2026 at 22:10, 30 days 17 hours ago Abivax Secures $920 Million in Public Offering Biotechnology Abivax Ulcerative Colitis Public Offering American Depositary Shares
PRESS RELEASE published on 07/06/2026 at 22:05, 30 days 17 hours ago Abivax annonce la réalisation de son offre au public de 920 millions de dollars Abivax réalise son offre publique de 920 millions de dollars pour le développement de thérapies biotechnologiques. Les actions sont cotées sur Euronext Paris et le Nasdaq Biotechnologie Abivax Offre Publique Thérapies Cotées
PRESS RELEASE published on 07/06/2026 at 22:05, 30 days 17 hours ago Abivax annonce la réalisation de son offre au public de 920 millions de dollars Abivax annonce la réalisation de son offre au public de 920 millions de dollars. La société de biotechnologie lève des fonds pour ses thérapies contre les maladies inflammatoires Biotechnologie Abivax Offre Publique Maladies Inflammatoires Millions De Dollars
PRESS RELEASE published on 07/06/2026 at 22:05, 30 days 17 hours ago Abivax Announces Closing of $920 Million Public Offering Abivax closes $920 million public offering, strengthening financial position. Proceeds to support operations until Q4 2029. Leerink Partners, Morgan Stanley, Piper Sandler, Guggenheim Securities involved in the offering Financial Position Abivax Morgan Stanley Public Offering Leerink Partners
BRIEF published on 07/02/2026 at 08:05, 1 month 4 days ago Abivax conclut une offre d'ADS avec succès Biotechnologie Abivax Investissements Ads Offre
BRIEF published on 07/02/2026 at 08:05, 1 month 4 days ago Abivax successfully concludes an ADS offer Biotechnology Abivax Offer Ads Investments
BRIEF published on 07/02/2026 at 08:05, 1 month 4 days ago L'offre d'Abivax rapporte 920 millions de dollars suite à l'exercice de surallocation. Biotechnologie Abivax Obefazimod Augmentation De Capital Offre ADS
BRIEF published on 07/02/2026 at 08:05, 1 month 4 days ago Abivax's Offering Yields $920M Following Over-Allotment Exercise Biotechnology Abivax Obefazimod Capital Increase ADS Offering
Published on 08/06/2026 at 15:00, 34 minutes ago Norsemont Strategically Expands Choquelimpie Land Package To 9,048 Hectares
Published on 08/06/2026 at 14:30, 1 hour 4 minutes ago Loar Holdings Inc. Reports Q2 2026 Record Results and Upward Revision to 2026 Outlook
Published on 08/06/2026 at 14:30, 1 hour 4 minutes ago NV Gold Announces Expansion of Holdings and Drill Program at the Slumber Gold Project in Nevada
Published on 08/06/2026 at 14:30, 1 hour 4 minutes ago AIAI Holdings' MediGuide Launches Longevity Intelligence, Redefining Personalized Preventive Healthcare
Published on 08/06/2026 at 14:00, 1 hour 34 minutes ago Adcore to Publish Second Quarter 2026 Results on August 13, 2026
Published on 08/06/2026 at 15:18, 16 minutes ago Form 8.3 - The Vanguard Group, Inc.: Picton Property Income Limited
Published on 08/06/2026 at 15:17, 16 minutes ago Form 8.3 - The Vanguard Group, Inc.: Intertek Group plc
Published on 08/06/2026 at 08:44, 6 hours 49 minutes ago IDI annonce la cession du groupe Talis à son fondateur, Serge Marcillaud, accompagné de l'équipe dirigeante
Published on 08/06/2026 at 08:00, 7 hours 34 minutes ago EURAZEO ENTRE EN DISCUSSIONS EXCLUSIVES AVEC PARTNERS GROUP EN VUE DE LA CESSION DE SA PARTICIPATION DANS AROMA-ZONE ET DE SON RÉINVESTISSEMENT À SES CÔTÉS
Published on 08/06/2026 at 08:00, 7 hours 34 minutes ago EURAZEO ENTERS INTO EXCLUSIVE DISCUSSIONS WITH PARTNERS GROUP REGARDING THE CONTEMPLATED SALE OF ITS STAKE IN AROMA-ZONE AND ITS REINVESTMENT
Published on 08/06/2026 at 07:48, 7 hours 45 minutes ago ENGIE - Déclaration du nombre total d'actions et de droits de vote au 31 juillet 2026
Published on 08/05/2026 at 18:00, 21 hours 34 minutes ago Informations relatives au nombre total de droits de vote et d’actions composant le capital social au 31 juillet 2026
